MNOV

Business Context and Reporting Period

Company: MediciNova, Inc.
Filing Type: Form 10-K (Special Financial Report pursuant to Rule 15d-2)
Reporting Period: Fiscal year ended December 31, 2004
Business Overview: MediciNova is a specialty pharmaceutical company in the development stage, focused on acquiring, developing, and commercializing innovative pharmaceutical products. The company operates through strategic core programs (direct commercialization) and partnering programs (licensing to larger pharma companies). As of December 31, 2004, the company had six licensed compounds in various stages of development, including two Phase I trials in its strategic core program and two Phase II trials in its partnering program.

Key Financial Metrics

Debt and Liquidity: The company had no long-term debt as of December 31, 2004. Liquidity was significantly strengthened by the sale of Series C redeemable convertible preferred stock in September 2004, resulting in net proceeds of approximately $43.4 million. Cash used in operating activities was $13.5 million, while cash provided by financing activities was $59.2 million.

Material Changes vs. Prior Period

• Revenue: The company generated $490,000 in revenue in 2004, compared to zero in 2003. This revenue was derived from development management contracts with Asahi Kasei Pharma Corporation and Argenes Inc., consisting of consulting fees and pass-through clinical costs.
• Operating Expenses: Total operating expenses surged to $49.1 million in 2004 from $6.3 million in 2003. This increase was primarily driven by a $34.2 million non-cash charge for stock-based compensation related to founders' warrants and employee options.
• Research and Development (R&D): R&D expenses increased to $11.2 million in 2004 from $4.7 million in 2003. The increase was due to higher clinical trial costs and licensing fees for strategic core and partnering programs.
• General and Administrative (G&A): G&A expenses rose to $3.2 million in 2004 from $1.5 million in 2003, reflecting expanded administrative functions and professional fees.
• Stock-Based Compensation: A significant non-cash expense of $34.3 million was recorded in 2004 due to the adjustment of founders' warrants and the amortization of deferred compensation. No such expense was recorded in 2003.

Guidance, Outlook, and Risks

Outlook: Management expects to incur substantial net losses for the next several years as it continues to develop product candidates. The company anticipates that existing cash and cash equivalents will be sufficient to meet projected operating requirements through at least December 31, 2006. The company does not expect to generate significant revenue from licensing, milestones, or product sales within the next 12 to 18 months.

Risks and Contingencies:

• Capital Requirements: The company relies on equity financing and may need to raise additional funds. Failure to obtain adequate financing could require delaying or eliminating research programs.
• Development Risks: Clinical development timelines and costs are uncertain. Failure to complete clinical trials or obtain regulatory approvals could materially adversely affect operations.
• Accounting Changes: The adoption of SFAS No. 123R (Share-Based Payment) is expected to increase operating expenses starting in the first interim period after June 15, 2005.
• License Obligations: The company has potential future milestone payments totaling approximately $90.35 million under various license agreements, contingent upon achieving specific development and regulatory milestones.

Key Facts for Investor Verification

• Recent IPO: The company completed an initial public offering (IPO) on February 4, 2005, selling 30 million shares at approximately $3.88 per share, raising net proceeds of $104.3 million. An additional 1.57 million shares were sold via an overallotment option on March 8, 2005.
• Non-Cash Charges: The reported net loss for 2004 includes a $34.3 million non-cash stock-based compensation charge. Investors should verify the impact of future stock-based compensation under SFAS 123R.
• Preferred Stock Conversion: All outstanding Series A, B, and C preferred stock automatically converted to common stock upon the closing of the IPO. The pro forma net loss per share assuming conversion was $(1.85) for 2004.
• Liquidity Position: As of December 31, 2004, the company held $50.8 million in cash and marketable securities, a significant increase from $5.5 million in 2003, primarily due to preferred stock sales.
• Development Stage: The company remains in the development stage with no commercial product sales. All revenue to date is from contract services, not product sales.